MedTrace Logo

Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel

NCT01276275 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7200

Last updated 2016-03-31

No results posted yet for this study

Summary

The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for the first time.

A further purpose is to ascertain and estimate the crude incidence rate of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.

Conditions

  • Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout

Interventions

DRUG

Risk of selected safety events

First time users of ticagrelor, clopidogrel and prasugrel, respectively

Sponsors & Collaborators

Principal Investigators

  • Helle Kieler, MD, PhD, Assoc Prof · Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01276275 on ClinicalTrials.gov